HIGH-DOSE BIOTIN TREATMENT FOR SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS MAY INTERFERE WITH THYROID ASSAYS.

OBJECTIVE To review cases and increase awareness in clinicians treating patients who may be taking biotin. METHODS We describe the presentation and workup of a woman with secondary progressive multiple sclerosis on high dose biotin with laboratory studies suggestive of thyrotoxicosis. RESULTS Plasma samples showed laboratory evidence of elevated thyroid hormone levels with elevated free thyroxine >7.8 ng/dl (reference interval (RI) 0.9-1.7 ng/dl) and decreased thyroid stimulating hormone <0.02 uIU/ml (RI 0.50-5.70 uIU/ml). Laboratory values normalized when biotin was withheld prior to repeat testing. CONCLUSIONS Our case report demonstrates that ingestion of high dose biotin in multiple sclerosis patients can cause interference with laboratory assessment of thyroid function. This interference causes laboratory values suggestive of thyrotoxicosis and can lead to unnecessary evaluation. Clinicians should be aware of the risk of laboratory interference in this patient demographic.

[1]  E. Tai,et al.  Macro-thyrotropin: a case report and review of literature. , 2012, The Journal of clinical endocrinology and metabolism.

[2]  R. Mcmahon.  Biotin in metabolism and molecular biology. , 2002, Annual review of nutrition.

[3]  R. Bitsch,et al.  Studies on bioavailability of oral biotin doses for humans. , 1989, International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition.

[4]  E. Diamandis,et al.  The biotin-(strept)avidin system: principles and applications in biotechnology. , 1991, Clinical chemistry.

[5]  S. Sobki,et al.  Interference by Biotin Therapy on Measurement of TSH and FT4 by Enzymeimmunoassay on Boehringer Mannheim ES700 Analyser , 1996, Annals of clinical biochemistry.

[6]  A. Tosti,et al.  Evidence‐based (S3) guideline for the treatment of androgenetic alopecia in women and in men , 2011, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[7]  M. Chan,et al.  Biotin interference on TSH and free thyroid hormone measurement. , 2012, Pathology.

[8]  D. Galanaud,et al.  High doses of biotin in chronic progressive multiple sclerosis: a pilot study. , 2015, Multiple sclerosis and related disorders.

[9]  N. Després,et al.  Antibody interference in thyroid assays: a potential for clinical misinformation. , 1998, Clinical chemistry.

[10]  G. Kearns,et al.  The clearance and metabolism of biotin administered intravenously to pigs in tracer and physiologic amounts is much more rapid than previously appreciated. , 2001, The Journal of nutrition.

[11]  W. Nyhan.  Inborn errors of biotin metabolism. , 1987, Archives of dermatology.

[12]  J. Doery,et al.  Positive and negative interference in immunoassays following biotin ingestion: a pharmacokinetic study. , 2012, Pathology.

[13]  D. Mock,et al.  Pharmacokinetics and pharmacodynamics of MD1003 (high-dose biotin) in the treatment of progressive multiple sclerosis , 2016, Expert opinion on drug metabolism & toxicology.